Oric Pharmaceuticals
Amber Wang is a Senior Bioinformatics Scientist at ORIC Pharmaceuticals Inc., where responsibilities include analyzing pre-clinical data to develop patient selection hypotheses for clinical trials and utilizing genomic datasets to identify target indications. Previous experience includes roles as a Bioinformatics Researcher at Genentech, focusing on multi-omics integration and cell interactions in immuno-oncology, and as a Data Scientist at Oncora Medical, where insights derived from electronic healthcare data informed clinical care. Amber holds a PhD in Systems Pharmacology and Translational Therapeutics from the University of Pennsylvania and has a Bachelor's Degree in Pharmacy from National Taiwan University. Additional experience includes leadership roles in academic affairs and research at the University of Pennsylvania, along with internships in healthcare consulting and pharmacy.
Oric Pharmaceuticals
ORIC Pharmaceuticals is a privately held, clinical-stage oncology company focused on making cancer treatments more effective by addressing mechanisms of resistance. ORIC's lead asset, ORIC-101, is a potent and selective small-molecule antagonist of the glucocorticoid receptor. ORIC's pipeline targets other undisclosed mechanisms of oncology therapy resistance. ORIC's scientific founders are Drs. Charles Sawyers, MD, and Scott Lowe, PhD, who have strong records of discovering innovative treatments and targets in cancer. The company has assembled strong leadership and scientific teams and a board with extensive experience in drug development and financing. ORIC is funded by leading biotechnology investors, including The Column Group, Topspin Partners, OrbiMed Advisors, EcoR1 Capital, Fidelity Management & Research Company, Trinitas Capital, Foresite Capital, Taiho Ventures, Memorial Sloan Kettering, Kravis Investment Partners, NS Investment and City Hill Ventures. ORIC is headquartered in South San Francisco, California.